Keyphrases
ALK Inhibitor Resistance
10%
BRAF mutant
12%
Cellular Heterogeneity
12%
Droplet Digital PCR (ddPCR)
12%
Drug Susceptibility Testing
12%
Embedded Control
10%
Highly Sensitive
12%
In Vitro Production
12%
In Vitro Resistance
12%
Inter-patient Variability
12%
Limit of Detection
12%
Low Abundant
12%
MEK Inhibitor (MEKi)
25%
Non-small Cell Lung Cancer (NSCLC)
50%
Non-target-site Resistance
37%
Novel Mechanism
12%
Patient Subgroups
12%
Personalized Treatment Selections
12%
Pleural Effusion
12%
Rate Heterogeneity
12%
Resistance Mechanisms
25%
Resistance mutations
50%
Resistant Clones
12%
Second-generation Tyrosine Kinase Inhibitors
50%
Specific mutation
12%
Subclone
12%
Success Rate
12%
Targeted Therapy
12%
Therapeutic Failure
12%
Treatment Resistance
12%
Treatment-seeking Sample
12%
Tumor Cells
12%
Tyrosine Kinase Inhibitor
50%
Tyrosine Kinase Inhibitor Therapy
12%
Whole Exome Sequencing
12%
Medicine and Dentistry
ALK Inhibitor
50%
Biopsy Technique
30%
Droplet Digital Polymerase Chain Reaction
28%
Epidermal Growth Factor Receptor
50%
Formaldehyde
50%
Fusion Gene
50%
Gene Frequency
8%
Leukocyte
16%
Lung Cancer
100%
Neoplasm
30%
Non Small Cell Lung Cancer
36%
Progression Free Survival
16%
Protein Tyrosine Kinase
10%
Resistance Mutation
58%
Survival Time
8%
Tyrosine-Kinase Inhibitor
50%
Biochemistry, Genetics and Molecular Biology
Droplet Digital Polymerase Chain Reaction
76%
Drug Sensitivity
16%
Epidermal Growth Factor Receptor
66%
Exome Sequencing
16%
Fusion Gene
50%
Gene Frequency
10%
Leukocyte
20%
Progression Free Survival
20%
Receptor Tyrosine Kinase
25%
Survival Time
10%
Tyrosine Kinase
25%
Tyrosine Kinase Inhibitor
100%
